Molecular Therapy (2011); 19 11, 1971–1980. doi:10.1038/mt.2011.157
Adam K Bevan1,2, Sandra Duque3, Kevin D Foust1, Pablo R Morales4, Lyndsey Braun1, Leah Schmelzer1, Curtis M Chan5, Mary McCrate1,6, Louis G Chicoine1,6, Brian D Coley7, Paul N Porensky3,8, Stephen J Kolb3,9, Jerry R Mendell1,6,9, Arthur HM Burghes2,3 and Brian K Kaspar1,2,3,6,10
1Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA
2Integrated Biomedical Sciences Graduate Program, The Ohio State University, Columbus, Ohio, USA
3Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio, USA
4The Mannheimer Foundation, Inc., Homestead, Florida, USA
5Special Pathology Services, Charles River, Preclinical Services, Reno, Nevada, USA
6Department of Pediatrics, The Ohio State University/Nationwide Children's Hospital, Columbus, Ohio, USA
7Department of Radiology, The Ohio State University, Columbus, Ohio, USA
8Department of Neurological Surgery, The Ohio State University, Columbus, Ohio, USA
9Department of Neurology, The Ohio State University, Columbus, Ohio, USA
10Department of Neurosciences, The Ohio State University, Columbus, Ohio, USA
Our findings support the use of AAV9 for gene transfer to the CNS for disorders in pediatric populations.
MT-OPEN FULL TEXT
Subscribe to:
Posts (Atom)
